SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

Analyst Ratings

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Show:
DateFirmActionRatingPrice TargetActions
7/9/2015BWS FinancialDowngradeHold -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2015MLV & Co.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2015AegisReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012$0.18$0.20ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2012$0.11$0.15ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateHeadline
07/24/16 10:21 AMAccounts Payable For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Stood At $3.267 - RealistInvestor.com
07/23/16 10:06 AMSciClone Pharmaceuticals Inc. (SCLN) is Trading Higher on Unusual Volume for July 21 - Equities.com
07/22/16 06:05 PMChecking in on Stock Volatility for: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily
07/22/16 06:05 PMSciclone Pharmaceuticals (NASDAQ:SCLN) Short Interest Decreased By 2.6% - Press Telegraph
07/22/16 06:05 PMSciClone Pharmaceuticals Inc. (SCLN) Dropped After Strategic Review Concluded - RTT News
07/21/16 09:09 AMTrading Action Review: Watching Unusual Volume on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily
07/21/16 09:09 AMTraders Alert – SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Financial Breaking News (press release)
07/21/16 09:09 AMYesterday Trends to Watch: Express Scripts (ESRX) , SciClone Pharmaceuticals, (SCLN) - Street Updates
07/21/16 09:09 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Spurns Buyout Offers - Scibility Media
07/21/16 09:09 AMSciClone Pharmaceuticals Inc. (SCLN) Drops 20.81% on July 19 - Equities.com
07/20/16 11:52 AMETF’s with exposure to SciClone Pharmaceuticals, Inc. : July 20, 2016 -
07/20/16 09:11 AMSciClone Pharmaceuticals Inc. (SCLN) Dropped After Strategic Review Concluded
07/19/16 06:28 PMSciclone Pharma (SCLN) Says No Longer in Talks with Potential Acquirers; Offers FY16 Outlook
07/19/16 06:28 PMSciClone Pharmaceuticals' stock tumbles after ending discussions with acquirers
07/19/16 01:37 PMSciClone Plummets After Cutting Guidance, Says It's Not Talking To Any Acquirers - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) revealed an update on its tactical review process, which was disclosed in February. According to the company, it is no longer pursuing any active discussions with any possible acquirers that were undertaken as part of its tactical review process. The stock plunged 20.66 percent on Tuesday at time of writing. The company indicated it intends to remain an independent publicly traded company as it continued to implement its tactical growth plan for its core commercial business. SciClone indicated that during the part of the tactical review ...Full story available on Benzinga.com
07/19/16 07:25 AMSciclone Pharma (SCLN) Says No Longer in Talks with Potential Acquirers; Offers FY16 Outlook - StreetInsider.com
07/19/16 05:04 AM6:04 am SciClone Pharma updates FY16 EPS & revenue guidance in connection with its previous announcement that it is no longer continuing active discussions with potential acquirers -
07/19/16 05:00 AMSciClone Provides Update On Strategic Review Process - [PR Newswire] - The Company announced that it is no longer continuing active discussions with potential acquirers which were undertaken as part of its strategic review process, and plans to remain an independent publicly traded company as it continues to execute on its strategic growth plan for its core commercial business.
07/17/16 05:42 PMNext Weeks Broker Price Targets For SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Fiscal Standard
07/17/16 10:23 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Quarterly Accounts Payable At $3.267 Millions - RealistInvestor.com
07/15/16 11:32 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Current Analyst Ratings - Fiscal Standard
07/12/16 06:35 PMStock on the Rise for the Quarter: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Engelwood Daily
07/12/16 06:35 PMSciclone Pharmaceuticals (NASDAQ:SCLN) Shorted Shares Increased By 3.11% - Press Telegraph
07/11/16 08:58 AMSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : July 11, 2016 -
07/10/16 05:32 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Broker Price Targets For The Coming Week - Fiscal Standard
07/08/16 06:17 PMSciclone Pharmaceuticals (NASDAQ:SCLN) Shorted Shares Increased 3.11% After Market Selling - Engelwood Daily
07/07/16 09:04 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Updated Price Targets - FTSE News
07/06/16 01:39 PMETF’s with exposure to SciClone Pharmaceuticals, Inc. : July 6, 2016 -
06/30/16 06:36 PMSome Traders Are Very Bullish on SciClone Pharmaceuticals, Inc. After Forming Bullish Wedge Up Chart Pattern - Engelwood Daily
06/28/16 11:06 AMSciclone Pharmaceuticals (NASDAQ:SCLN) Short Interest Increased By 3.11% - Press Telegraph
06/27/16 03:29 PMSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : June 27, 2016 -
06/24/16 08:01 AMSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : June 24, 2016 -
06/23/16 08:55 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Stock Momentum Hits Strength - CML News
06/20/16 05:58 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/15/16 06:13 PMSciClone Pharmaceuticals Inc. (SCLN) is Trading Higher on Unusual Volume for June 13 - Equities.com
06/15/16 11:36 AMSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/14/16 06:00 PMSciClone Pharmaceuticals Inc. (SCLN) Jumps 5.36% on June 13 - Equities.com
06/09/16 06:48 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Fundamental Star Rating Report - CML News
06/04/16 09:17 AMBiotech Stocks Update: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) , SciClone Pharmaceuticals, Inc ... - Is stories
06/03/16 02:40 PMETF’s with exposure to SciClone Pharmaceuticals, Inc. : June 3, 2016 -
06/03/16 02:19 PM3 Biotech Stocks Headed for New Highs (SCLN, SUPN) -
06/03/16 09:16 AMSciClone Pharmaceuticals Inc. (SCLN) is Trading Lower on Unusual Volume for June 01 - Equities.com
06/03/16 09:16 AMSciClone Pharmaceuticals Inc. (SCLN) Hits New 52-week High During June 01 Session - Equities.com
06/02/16 06:47 PMTraders Actions to Focus: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) , Raptor Pharmaceutical Corp. (NASDAQ ... - Street Updates - Traders Actions to Focus: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) , Raptor Pharmaceutical Corp. (NASDAQ ...Street UpdatesOn 6/1/2016, SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) highlighted downward shift of -0.64% or -0.09 points to $14.06. The company traded a volume of 1.29 million shares over average volume of 611.5 thousand shares. Trailing twelve month period, ...and more »
06/02/16 09:24 AMAnalyst Recommended These Stocks for Investors: Unit Corporation (NYSE:UNT), SciClone Pharmaceuticals, Inc ... - Beacon Chronicle - Beacon ChronicleAnalyst Recommended These Stocks for Investors: Unit Corporation (NYSE:UNT), SciClone Pharmaceuticals, Inc ...Beacon ChronicleSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) currently has High Price Target of $10. The Low and Mean Price Targets are $10 and $10 respectively. These price targets are a consensus analysis of 1 brokers. When having a look at Recommendation ...and more »
06/02/16 09:24 AMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Change In Inventory At $1.432 Millions - RealistInvestor.com - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Change In Inventory At $1.432 MillionsRealistInvestor.comSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) accounts payable was $4.495 millions for the fiscal closed 2015-12-31. For the quarter ended 2015-12-31 it was $4.495 millions. At the end of the year 2015-12-31, the deviation in accounts payable was ...
06/01/16 06:55 PMSciClone Pharmaceuticals, Inc. (SCLN) Sees 52-Week High - Finance Daily - SciClone Pharmaceuticals, Inc. (SCLN) Sees 52-Week HighFinance DailyThe stock of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) hit a new 52 week high point reaching $14.22 in trading on Wednesday. Shares closed down 0.64% when all was said and done. Volume came in at 1,234,180 and the stock hit $13.91 at its ...What's Ahead for SciClone Pharmaceuticals, Inc. After Reaching 52-Week High?The Postall 2 news articles »
05/31/16 06:38 PMSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Quarterly EPS Estimate At $0.00 - Investor Newswire - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Quarterly EPS Estimate At $0.00Investor NewswireFirst Call stated that SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) can touch $10.00 in coming one year. For the next quarter, the per-share earnings target is $0.00 and for ongoing fiscal at $0.33. EPS target for next year is $0.68 versus the mean EPS ...and more »
05/31/16 06:38 PMSciClone Pharmaceuticals Inc. (SCLN) Jumps 7.81% on May 31 - Equities.com - SciClone Pharmaceuticals Inc. (SCLN) Jumps 7.81% on May 31Equities.comSciClone Pharmaceuticals Inc. (SCLN) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 7.81% to $14.15, representing a gain of $1.025 per share. Some 856,607 shares traded hands on 6,542 trades, compared ...and more »
05/26/16 01:07 PMNantahala Capital Management LLC Increased Sciclone Pharmaceuticals INC (NASDAQ:SCLN) by $15.99 Million as ... - CCH Daily News - Nantahala Capital Management LLC Increased Sciclone Pharmaceuticals INC (NASDAQ:SCLN) by $15.99 Million as ...CCH Daily NewsWilmot B. Harkey increased its stake in Sciclone Pharmaceuticals Inc (NASDAQ:SCLN) by 254.12% based on its latest 2016Q1 regulatory filing with the SEC. Nantahala Capital Management Llc bought 1.45M shares as the company's stock rose 26.73% with ...and more »

Social

About SciClone Pharmaceuticals

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SCLN
  • CUSIP: 80862K10
Key Metrics:
  • Previous Close: $10.16
  • 50 Day Moving Average: $13.07
  • 200 Day Moving Average: $11.28
  • P/E Ratio: 18.81
  • P/E Growth: 0.00
  • Market Cap: $507.08M
  • Beta: 1.8
  • Current Year EPS Consensus Estimate: $0.72 EPS
Additional Links:
SciClone Pharmaceuticals (NASDAQ:SCLN) Chart for Wednesday, July, 27, 2016